Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
J. P. Murad, O. A. Lin, E. V. Paez Espinosa and F. T. Khasawneh
Affiliation: Department of Pharmaceutical Sciences, Western University of Health Sciences, 309 E. Second St., Pomona, CA 91766, USA.
The premise of targeted therapy was born from an intimate understanding of the unique biological
pathways and endpoints which are implicated in the development of different disease states and conditions. In
addition, the identification of the most appropriate drugs to use for targeted drug therapy has aided in growing
interest of the pharmaceutical industry to allocate more resources to monoclonal antibody (mAb) therapeutics.
This being the case, it is important to understand antibody based therapeutics, some of the currently Food and
Drug Administration (FDA)-approved mAbs in different disease states, as well as the future direction of mAb
therapies. In this article, we will provide a critical overview, and discuss a selection of antibody based
therapeutics, including their bioengineered structural and functional elements. Furthermore, a segment of the
currently FDA-approved mAb antibody therapies, those in research, or in investigation for disease states and
conditions ranging from autoimmune disease, inflammatory response, immunosuppression, cancer, including
antibody-drug conjugates, immunotherapy, and exciting prospects for antiplatelet and antithrombotic
monoclonal antibody therapeutics will be reviewed. Finally, we will discuss our predictions and aspirations for
the future directions of mAb-based therapeutic interventions.
Keywords: Antibody, antibody based therapeutics, antithrombotic agents, immune response, monoclonal
Rights & PermissionsPrintExport